14
Oct2021

On August 5, 2021, PRIM&R hosted a webinar entitled IRB Review of Expanded Access Protocols that Collect Real World Data: Considerations and Guidance. During this webinar, speakers discussed ethical and analytical considerations when collecting real world data from Expanded Access. Today, they provide further information and answer follow-up questions. Read more

7
Oct2021

The PRIM&R Knowledge Center houses a wide range of resources to keep you inspired and informed for your work in research ethics and oversight! As you familiarize yourself with the Knowledge Center, we want to direct you to some of our notable resources. Today, we'll share our top five diversity, equity, and inclusion resources for IRBs and IACUCs. Read more

23
Sep2021

In 2019, as part of a larger process of evaluating PRIM&R’s awards and recognitions and how they support and promote the organization’s mission and core values, we decided to retire the Pillar of PRIM&R designation. Before doing so, we reviewed our roster and the history of the organization to identify and honor anyone who played a key role in the organization’s founding and early growth who had not yet been recognized in this manner. Our review resulted in a list of seven additional individuals whom we believe are deserving of the designation of Pillar of PRIM&R, and are honored to now name Pillars of PRIM&R. Read more

13
Sep2021

Biomedical Research Awareness Day (BRAD) is an international outreach program that seeks to increase public awareness about animal roles in biomedical research and the resulting medical advancements that benefit both humans and animals. BRAD highlights the importance of animal studies and research organizations’ commitment to providing excellent animal care. It also builds a research advocate community and showcases biomedical research and laboratory animal care and medicine careers. Read on to see how you can celebrate BRAD in 2021. Read more

8
Sep2021

IRBs come in many types, focusing on dramatically different categories of research from Phase I drug research to studies focused solely on education and social science. It may seem at first that the latter entails simpler ethical problems than, say, multisyllabic first-in-human drug trials for cancer, but very low-risk nonmedical research presents its own challenges for the IRB. Read more